Drug intelligence / Profile preview

raphamin

Development stage: Phase 3
Lead developer: Materia Medica Holding
Modality: Antibody-Based Therapeutics
Administration: Oral

Overview

Raphamin is an investigational drug evaluated in clinical trials for the treatment of community-acquired pneumonia and other conditions. It is administered orally, typically as a tablet. The precise mechanism of action, active ingredient(s), and pharmacological class are not specified in publicly available sources. Raphamin has been studied in combination with standard antibiotics such as amoxicillin + clavulanic acid (amoxiclav) for pneumonia, suggesting it may be intended as an adjunctive therapy to enhance or support antibiotic treatment[8][3]. No detailed information on its molecular target, chemical structure, or whether it is a small molecule or biologic has been disclosed.

Brand names: raphamin
Other names: raphamin

Targets

MHC I (MHC class I})

Beyond the preview

Go deeper on raphamin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on raphamin.

Explore the full profile